Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Reaffirmed as Sector Perform by Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “sector perform” rating reiterated by equities research analysts at Royal Bank Of Canada in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $737.00 price target on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target suggests a potential upside of 0.68% from the company’s current price.

Other research analysts have also issued research reports about the stock. Citigroup raised their price target on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Leerink Partners upped their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 20th. Wells Fargo & Company boosted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Finally, Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $809.50.

Regeneron Pharmaceuticals Trading Down 0.4%

REGN traded down $2.75 during midday trading on Tuesday, hitting $732.06. 103,346 shares of the company were exchanged, compared to its average volume of 827,921. The firm’s 50 day moving average price is $786.71 and its 200-day moving average price is $720.83. Regeneron Pharmaceuticals has a 1-year low of $541.00 and a 1-year high of $859.34. The firm has a market capitalization of $75.37 billion, a P/E ratio of 18.10, a P/E/G ratio of 1.49 and a beta of 0.16. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $12.81 earnings per share. As a group, equities analysts forecast that Regeneron Pharmaceuticals will post 44.25 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director owned 603 shares in the company, valued at approximately $512,550. This represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the sale, the executive vice president directly owned 12,003 shares of the company’s stock, valued at $10,291,252.17. This trade represents a 8.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 3,946 shares of company stock valued at $3,302,458. Corporate insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Versant Capital Management Inc grew its position in Regeneron Pharmaceuticals by 55.2% in the 3rd quarter. Versant Capital Management Inc now owns 534 shares of the biopharmaceutical company’s stock valued at $405,000 after purchasing an additional 190 shares during the period. Envestnet Asset Management Inc. raised its holdings in Regeneron Pharmaceuticals by 0.6% during the second quarter. Envestnet Asset Management Inc. now owns 109,838 shares of the biopharmaceutical company’s stock worth $68,488,000 after buying an additional 686 shares during the last quarter. Andra AP fonden lifted its stake in shares of Regeneron Pharmaceuticals by 583.2% in the second quarter. Andra AP fonden now owns 28,912 shares of the biopharmaceutical company’s stock valued at $18,028,000 after buying an additional 24,680 shares in the last quarter. State Street Corp lifted its stake in shares of Regeneron Pharmaceuticals by 3.6% in the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after buying an additional 170,210 shares in the last quarter. Finally, Tidal Investments LLC grew its holdings in shares of Regeneron Pharmaceuticals by 10.7% during the second quarter. Tidal Investments LLC now owns 43,896 shares of the biopharmaceutical company’s stock valued at $27,371,000 after buying an additional 4,244 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Sanofi alliance expansion provides significant potential funding. Regeneron will receive $1 billion upfront and could earn up to an additional $7 billion in milestones under an expanded collaboration with Sanofi covering four next-generation, long-acting antibodies targeting type 2 inflammation. The companies will share development and commercialization costs and future profits. The deal expands an alliance that produced Dupixent and strengthens REGN’s long-term immunology pipeline. Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
• Positive Sentiment: Analysts became more bullish. Jefferies raised its price target from $870 to $930 and maintained a Buy rating, while Argus upgraded REGN from Hold to Buy with an $850 target. The revisions reflect confidence in the company’s pipeline, business development prospects and valuation. Regeneron price target increase
• Positive Sentiment: Trevogrumab delivered encouraging obesity-treatment data. In the Phase 2 COURAGE trial, trevogrumab prevented approximately 70% of the lean-mass loss associated with semaglutide in an MRI substudy. The result supports Regeneron’s effort to address muscle loss, a major concern with GLP-1 weight-loss therapies, and could create a valuable combination-treatment opportunity. Phase 2 COURAGE Trial Results
• Positive Sentiment: Ubamatamab showed activity in difficult-to-treat ovarian cancer. The drug produced a 73% objective response rate and an 11-month median progression-free survival in 11 heavily pretreated patients with low-grade serous ovarian cancer. The findings could support further development in a setting with limited treatment options. Ubamatamab Ovarian Cancer Study
• Neutral Sentiment: Clinical evidence remains preliminary. The ovarian-cancer results came from a small, early-stage cohort, so investors may want larger and later-stage trials before assigning substantial commercial value to ubamatamab. RBC separately maintained a Sector Perform rating, tempering the more optimistic analyst views. Regeneron Ovarian Cancer Trial Data

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.